Development of Potential Pharmacological Targets to Normalize Gene Expression in Islets of Type 2 Diabetic Patients

Area of Science:

• Genomics and Bioinformatics
• Metabolic Diseases Research
• Pharmacological Target Identification

Background:

• Type 2 diabetes (T2D) is a prevalent and challenging metabolic disorder with increasing incidence.
• Existing pharmacological treatments for T2D often show limited efficacy, necessitating novel therapeutic strategies.
• Understanding the molecular underpinnings of T2D in pancreatic islets is crucial for developing improved treatments.

Purpose of the Study:

• To identify molecular alterations in pancreatic islets associated with T2D.
• To integrate multi-omics data for a comprehensive understanding of T2D pathogenesis.
• To discover potential pharmacological targets and candidate drugs for T2D treatment using bioinformatics.

Main Methods:

• Multi-omics data integration using OmicsNet to analyze T2D-related molecular changes.
• Protein-protein interaction network visualization, gene ontology, and KEGG pathway analysis.
• Virtual screening of experimental drugs against identified hub genes and molecular docking using CB-Dock2.

Main Results:

• Key molecular alterations in T2D pancreatic islets include enzyme binding, mitochondrial metabolism, and transcription factor dysregulation.
• These alterations impact critical pathways such as glucose uptake, insulin signaling, and secretion.
• Molecular docking identified SRC, AKT1, CREBBP, and HSP90AA1 as therapeutic targets for five specific experimental drugs (DB02729, DB04877, DB07970, DB07789, DB03373).

Conclusions:

• The study identified significant molecular alterations in the pancreas of T2D patients.
• Ten hub genes and five experimental drugs were identified as potential therapeutic interventions for T2D.
• Further research is warranted to validate these findings and their clinical applicability.